Selective mTOR inhibition via FLCN drives TFE3-dependent VLDL-TG secretion and protects from MAFLD/MASH

Hepatic lipid homeostasis is controlled by multiple processes, including VLDL-TG secretion. We have previously shown that the FLCN/TFE3 branch of mTORC1 signaling controls hepatic fatty acid oxidation and de novo lipogenesis to protect mice from MAFLD. We now show that the FLCN/TFE3 pathway also controls VLDL-TG secretion via direct transcriptional activation of a broad program of genes involved in VLDL-TG secretion, including PCYT1A, the rate-limiting step of phosphatidylcholine synthesis. Loss of hepatic FLCN upregulates VLDL-TG secretion and prevents MAFLD, and this protection requires TFE3 and PCYT1A. The data unveil a new pathway that orchestrates multiple steps of VLDL-TG synthesis and secretion. The data also highlight that suppressing the selective FLCN/TFE3 branch of mTORC1 signaling maximizes hepatic lipid clearance by coordinately promoting fatty acid oxidation, suppressing de novo lipogenesis, and boosting VLDL-TG secretion, providing an attractive therapeutic target for the treatment of MAFLD.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2026-11-18
DOI
https://doi.org/10.1038/s41467-026-79397-6
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Selective mTOR inhibition via FLCN drives TFE3-dependent VLDL-TG secretion and protects from MAFLD/MASH

Wei Zhou, Bridget S. Gosis, Zoltan Pierre Arany, Cholsoon Jang et al.
1 links
Nature Communications
Liver Disease Diagnosis and Treatment
article

Selective mTOR inhibition via FLCN drives TFE3-dependent VLDL-TG secretion and protects from MAFLD/MASH

Wei Zhou, Bridget S. Gosis, Zoltan Pierre Arany, Cholsoon Jang, Kristina Li, Aalim M. Weljie, Jae Woo Jung, Chelsea L. Thorsheim, Paul M. Titchenell, Daniel James Boehmler, Megan C. Blair, Arin Cox, Jessie Axsom, Gabriel C. Durso, Sho Tanosaki
article en

Abstract

Hepatic lipid homeostasis is controlled by multiple processes, including VLDL-TG secretion. We have previously shown that the FLCN/TFE3 branch of mTORC1 signaling controls hepatic fatty acid oxidation and de novo lipogenesis to protect mice from MAFLD. We now show that the FLCN/TFE3 pathway also controls VLDL-TG secretion via direct transcriptional activation of a broad program of genes involved in VLDL-TG secretion, including PCYT1A, the rate-limiting step of phosphatidylcholine synthesis. Loss of hepatic FLCN upregulates VLDL-TG secretion and prevents MAFLD, and this protection requires TFE3 and PCYT1A. The data unveil a new pathway that orchestrates multiple steps of VLDL-TG synthesis and secretion. The data also highlight that suppressing the selective FLCN/TFE3 branch of mTORC1 signaling maximizes hepatic lipid clearance by coordinately promoting fatty acid oxidation, suppressing de novo lipogenesis, and boosting VLDL-TG secretion, providing an attractive therapeutic target for the treatment of MAFLD.

Nature Communications
University of California, Irvine (US), University of Pennsylvania (US)
University of Pennsylvania, National Institutes of Health, National Heart, Lung, and Blood Institute
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon